Automated antimicrobial susceptibility test offers MIC accuracy

Aug. 14, 2019
Instrument utilizes broth microdilution method to guide more targeted patient therapy and optimize patient outcomes.

Thermo Fisher Scientific announced the release of a new benchtop automated reading and incubation system for antimicrobial susceptibility testing (AST) that gives microbiology laboratories accurate MIC results needed to confidently select an effective antibiotic for critically ill patients while safeguarding future patient care through more successful antimicrobial stewardship.

Backed by a long history of AST accuracy, the company says its Sensititre ARIS HiQ AST System relies on broth microdilution, the industry’s gold standard, to provide a MIC result that supports the optimization of treatment decisions and ultimately, patient outcomes.

Thermo Fisher Scientific says the system adds value to laboratories that routinely retest invalid AST results or that require additional confirmatory testing prior to releasing results to clinicians. The immediate accuracy of phenotypically driven MIC values delivers reliable results while minimizing re-tests, and can support a reduction in hidden costs associated with reporting delays.

Through close collaboration with leading pharmaceutical companies, the Sensititre ARIS HiQ AST System also offers a wide, up-to-date selection of antimicrobials, enabling earlier access to the latest therapies for multidrug-resistant infections. In addition, laboratories can create their own custom AST plates from a selection of over 300 antimicrobials in broad dilution ranges to consolidate and reduce offline testing.

The Sensititre ARIS HiQ AST System has an expanded capacity of up to 100 Sensititre plates in a limited footprint that makes it possible to process more tests at one time while conserving valuable bench space. It also features an intuitive touchscreen user interface for convenient operation; 24/7 access to critical test information; and batch load and unload capability for improved testing workflow.

 “The availability of an AST device can determine whether or not a particular therapy can be used for a critically-ill patient,” said Bernd Hofmann, Vice President of Marketing, Microbiology, Thermo Fisher Scientific. “As the World Health Organization and Centers for Disease Control and Prevention continue to report on the increasing threat of antibiotic resistance, the ability to use these newer antimicrobials is more important than ever.”